攝護腺癌荷爾蒙治療與肌腱炎的相關性研究
柳瑞明1,2,3, 莊恆彰1, 許仁駿4
1衛生福利部桃園醫院 外科部 泌尿科;2國立陽明大學醫學系;3國防醫學院 生命科學研究所4花蓮慈濟醫院 癌症研究中心
The association between androgen deprivation therapy and the risk of tenosynovitis
Jui-Ming Liu1,2,3, Heng-Chang Chuang1, Ren-Jun Hsu 4
1Division of Urology, Department of Surgery Taoyuan General Hospital, Ministry of Health and Welfare
2 Department of Medicine, National Yang-Ming University, Taipei, Taiwan
3 Graduate Institute of Life Sciences, National Defense Medical Center
4 Cancer Medicine Center of Buddhist Hualien Tzu Chi Hospital, Tzu Chi University, Hualien, Taiwan
Background:
Androgen deprivation therapy (ADT) use in prostate cancer (PCa) patients has been reported to exacerbate the course of rheumatoid arthritis. To test the impact of ADT on the risk of tenosynovitis.
Methods:
We used data from the National Health Insurance Research Database of Taiwan between 2001 and 2013. There were 729 ADT patients comprised the study group with 729 matched non-ADT controls by propensity-score matched analysis. The demographic characteristics and comorbidities were used t test. Cox proportional hazards regression was used to calculate the hazard ratios (HR) for the risk of tenosynovitis.
Results:
A number of 224 (15.3%) patients with newly diagnosed tenosynovitis were identified. Compared with non-ADT patients, ADT patients had a lower risk of subsequent tenosynovitis with adjusted HR of 0.36 (95% confidence interval (CI) 0.27-0.48).
Conclusions:
ADT may decrease risk of tenosynovitis in PCa patients. Further studies are warranted to have fully investigation.